Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
67%(4 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
6
75%
Ph phase_1
2
25%

Phase Distribution

2

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
6(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (25.0%)
Phase 26 (75.0%)

Trials by Status

completed675%
not_yet_recruiting113%
terminated113%

Recent Activity

0 active trials
Showing 5 of 8
not_yet_recruitingphase_1

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

NCT07500298
completedphase_2

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT02243358
completedphase_2

Chemoradiation or Brachytherapy for Rectal Cancer

NCT02017704
completedphase_1

Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

NCT01420874
completedphase_2

Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)

NCT01363843
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07500298Phase 1

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Not Yet Recruiting
NCT02243358Phase 2

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Completed
NCT02017704Phase 2

Chemoradiation or Brachytherapy for Rectal Cancer

Completed
NCT01420874Phase 1

Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Completed
NCT01363843Phase 2

Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)

Completed
NCT01749956Phase 2

5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

Completed
NCT01508000Phase 2

Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases

Terminated
NCT01605305Phase 2

Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8